{"nctId":"NCT03093246","briefTitle":"Omega-3 Plus Low-dose Aspirin Daily Supplementation in Non-surgical Therapy to Treat Aggressive Periodontitis","startDateStruct":{"date":"2017-05-15","type":"ACTUAL"},"conditions":["Aggressive Periodontitis"],"count":38,"armGroups":[{"label":"Control group","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo","Procedure: Full-mouth ultrasonic debridement"]},{"label":"Test Group","type":"EXPERIMENTAL","interventionNames":["Dietary Supplement: Omega-3 polyunsaturated fatty acids","Drug: Aspirin","Procedure: Full-mouth ultrasonic debridement"]}],"interventions":[{"name":"Omega-3 polyunsaturated fatty acids","otherNames":["Fish oil"]},{"name":"Aspirin","otherNames":["acetylsalicylic acid"]},{"name":"Placebo","otherNames":[]},{"name":"Full-mouth ultrasonic debridement","otherNames":["Periodontal debridement"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* diagnosis of GAgP (AAP, 1999);\n* presence of ≥20 teeth;\n* presence of ≥ 6 sites presenting PD ≥ 5mm with bleeding on probing (BOP) and ≥2 sites with PD ≥7mm (including incisors and first molars, in addition to other two non-contiguous teeth);\n* good general health;\n* agree to participate in the study and sign a written informed consent. All subjects will be individually informed about the objectives, probable risks and benefits of the protocol treatment (according to Resolution nº196 of October 1996 and to the Professional Code of Dental Ethics - 179/93).\n\nExclusion Criteria:\n\n* pregnancy or lactating;\n* suffer from any systemic disease (e.g. cardiovascular disorders, diabetes, blood dyscrasias, immunodeficiency, etc) which could alter the course of periodontal disease;\n* took antimicrobials in the previous 6 months;\n* taking long-term anti-inflammatory drugs;\n* previous periodontal treatment within the last 12 months;\n* smoker ≥ 10 cigarettes.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"40 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Probing Depth","description":"Evaluate the difference between baseline and 6 months PD measures.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.88","spread":"0.15"},{"groupId":"OG001","value":"3.74","spread":"0.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.38","spread":"0.14"},{"groupId":"OG001","value":"3.26","spread":"0.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.37","spread":"0.14"},{"groupId":"OG001","value":"3.25","spread":"0.13"}]}]}]},{"type":"SECONDARY","title":"Change in Clinical Attachment Level","description":"Evaluate the difference between baseline and 6 months CAL measures.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.94","spread":"0.17"},{"groupId":"OG001","value":"4.01","spread":"0.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.58","spread":"0.17"},{"groupId":"OG001","value":"3.65","spread":"0.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.59","spread":"0.17"},{"groupId":"OG001","value":"3.64","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"Change in Bleeding on Probe","description":"Evaluate the difference between baseline and 6 months BoP measures","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.11","spread":"4.97"},{"groupId":"OG001","value":"44.58","spread":"3.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.27","spread":"3.72"},{"groupId":"OG001","value":"27.41","spread":"2.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.77","spread":"3.58"},{"groupId":"OG001","value":"26.17","spread":"2.18"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":19},"commonTop":[]}}}